Japanese Encephalitis News and Research

RSS
Japanese encephalitis (previously known as Japanese B encephalitis to distinguish it from von Economo's A encephalitis) is a disease caused by the mosquito-borne Japanese encephalitis virus. The Japanese encephalitis virus is a virus from the family Flaviviridae. Domestic pigs and wild birds are reservoirs of the virus; transmission to humans may cause severe symptoms. One of the most important vectors of this disease is the mosquito ''Culex tritaeniorhynchus''. This disease is most prevalent in Southeast Asia and the Far East.
Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Intercell reports EUR 255.2m net loss for full year 2010

Intercell reports EUR 255.2m net loss for full year 2010

Sanofi Pasteur, International Vaccine Institute support Dengue Vaccine Initiative

Sanofi Pasteur, International Vaccine Institute support Dengue Vaccine Initiative

Global Health Consortium to support development of vaccines to control dengue fever

Global Health Consortium to support development of vaccines to control dengue fever

Inviragen completes memorandum of understanding with Duke-NUS

Inviragen completes memorandum of understanding with Duke-NUS

Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval

Sinovac's inactivated EV71 vaccine clinical trial against HFMD receives Chinese SFDA approval

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Vaccine World Summit to be held in New Delhi 1-3 March, 2011

Vaccine World Summit to be held in New Delhi 1-3 March, 2011

Sinovac third quarter sales decrease 7% to $9.6 million

Sinovac third quarter sales decrease 7% to $9.6 million

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Intercell reports significant increase in second quarter revenue

Intercell reports significant increase in second quarter revenue

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Tamir Biotechnology's three compounds effective show potential for yellow fever

Tamir Biotechnology's three compounds effective show potential for yellow fever

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

Saint Louis University conducts research to find safe, effective vaccination for dengue

Saint Louis University conducts research to find safe, effective vaccination for dengue

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

Sinovac Biotech's fourth-quarter sales increase 194%

Sinovac Biotech's fourth-quarter sales increase 194%